Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$44.89 -0.27%

-$0.12 today

Market cap
$3.30B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.75M

Average 1.35M

ELVN Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Enliven Therapeutics, Inc.NASDAQ: ELVN

Investing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Investing cash flow turns positive

Q3 FY2026 investing cash flow was $26.33M, compared with -$4.06M a year earlier. Trailing-twelve-month investing cash flow was -$360.33M. Over 3 fiscal years it compounded at +557.4% a year.

Context

  • Investing cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near $26.33M or moves back toward the trailing-twelve-month quarterly average of -$90.08M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$26.33M+106.0% QoQ
Last fiscal yearDec 2025
-$173.84M+382.9% YoY
LTMSep 2026
-$360.33M+94.3% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+748.8%——
1 year+382.9%——
3-year CAGR+557.4%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(173.84M) USD
Year-over-year change
-382.9%

Investing Cash Flow vs competitors

How ELVN compares with its peers on the latest reported figures

  • ELVN's LTM Sep 2026 investing cash flow of $360.33M is the 2nd largest of the 11 companies compared; the peer median is $92.14M.
  • Its year-over-year change of +94.3% is the 6th highest of 11, against a peer median of +122.3%.
  • Over three fiscal years its annual growth of +557.4% compares with a peer median of +10.0%.
ELVN Competitors Peer median
Investing Cash Flow for ELVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.39B +250.0%——
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$360.33M +94.3%+557.4%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$244.94M -1297.9%—2366.5%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$234.28M +993.1%—107.9%
INCYIncyte CorporationLTM Jun 2026$224.83M +23174.4%+9.3%3.9%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$188.46M -277.0%+10.7%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$175.6M +256.1%-10.3%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$104.47M -32.9%——
EXELExelixis, Inc.LTM Jul 2026$93.01M +840.9%—3.8%
TYRATyra Biosciences, Inc.LTM Mar 2026$79.81M -5.5%——
NUVBNuvation Bio Inc.LTM Jun 2026$47.18M -124.8%+16.2%27.8%
Peer median (excluding ELVN) $92.14M+122.3%+10.0%27.8%

Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.74M)(37.66M)(71.58M)(89.02M)(103.69M)
Depreciation & Amortization115K215K297K317K263K
Deferred Income Tax(3.81M)0000
Stock-Based Compensation1.92M3.19M12.91M20.17M34.02M
Change in Working Capital3.57M438K1.4M(4.54M)(1.12M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.73M411K(2.25M)810K817K
Other Working Capital1.83M27K3.65M(5.35M)(1.94M)
Other Non-Cash Items3.81M1.74M(4.3M)(118K)232K
Operating Cash Flow(19.13M)(32.08M)(61.27M)(73.19M)(70.3M)
Capital Expenditures(191K)(612K)(149K)(44K)(158K)
Acquisitions (Net)035M000
Purchases of Investments(47.56M)(35M)(268.26M)(350.74M)(446.79M)
Sales of Investments45.94M41.88M120M313.91M272.9M
Other Investing Activities1.62M(41.88M)0873K213K
Investing Cash Flow(191K)(612K)(148.41M)(36M)(173.84M)
Debt Repayment00000
Common Stock Issued(1.02M)(1.23M)161.2M39.19M218.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(566K)73.09M93.98M0
Financing Cash Flow(1.02M)(1.8M)234.29M133.17M218.87M
Effect of Forex Changes00000
Net Change in Cash(20.34M)(34.49M)24.61M23.98M(25.28M)
Free Cash Flow(19.33M)(32.69M)(61.42M)(73.24M)(70.46M)

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Intrinsic Alpha fair value

Locked

Current Price

$44.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.